AZD4573 in Novel Combinations with Anti-cancer Agents in Patients with Advanced Blood Cancer

Study identifier:D8230C00002

ClinicalTrials.gov identifier:NCT04630756

EudraCT identifier:2020-001642-18

CTIS identifier:N/A

Recruitment Complete

Official Title

A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations with Anti-cancer Agents in Patients with Advanced Haematological Malignancies

Medical condition

Advanced Haematological Malignancies

Phase

Phase 1/2

Healthy volunteers

No

Study drug

AZD4573, Acalabrutinib

Sex

All

Actual Enrollment

40

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 17 Feb 2021
Primary Completion Date: 08 Sept 2023
Estimated Study Completion Date: 31 Dec 2024

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Parexel International

Inclusion and exclusion criteria